## Abstract Blood lymphocytes from tumor patients can specifically destroy cultivated neoplastic cells of the same histological origin as the tumors of the lymphocyte donors, irrespective of whether or not the donors have symptoms of growing tumor. The purpose of the present study was to investiga
Increase of lymphocyte-mediated tumor-cell destruction by certain patient sera
✍ Scribed by Ingegerd Hellström; Karl Erik Hellström; Glenn A. Warner
- Publisher
- John Wiley and Sons
- Year
- 1973
- Tongue
- French
- Weight
- 437 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Sera from one patient with an ovarian carcinoma, one with sarcoma, one with a breast carcinoma, and four patients with melanoma were found to “potentiate” (i.e. increase) the cytotoxic effect of blood lymphocytes reactive to the respective type of tumor target cells. This effect was specific. Furthermore, sera from the breast cancer and sarcoma patients and from one of the melanoma patients “armed” (i.e. made cytotoxic) lymphocytes from non‐reactive donors, not having (had) the respective tumor studied. The possible relevance, in vivo, of these findings, and the frequency with which they occur, need further clarification.
📜 SIMILAR VOLUMES
## Abstract Two methylcholanthrene (MCA)‐induced sarcomas were used as targets in a criss‐cross pattern to study lymph‐node‐cell (LNC)‐mediated cytotoxic reactions to tumor‐specific antigens in a 26 h microcytotoxicity assay. Destruction of plated tumor cells by syngeneic LNC from specifically tumo
## Abstract Sera from patients with growing neoplasms have been previously shown capable of specifically blocking the cytotoxic effect of lymphocytes immune to tumor‐associated antigens (TAA) of the respective patients' neoplasms. The present investigation demonstrates that a similar blocking activ
## Abstract IgG fractions from serum of patients with transitional‐cell carcinoma of the urinary bladder (TCC), patients with carcinoma of the prostate (CC) and healthy donors (HD) were tested for their capacity to induce antibody‐dependent lymphocyte‐mediated cytotoxicity (ADCC) to tumor cells in